Bristol-Myers Squibb’s Orencia Garners Greatest Patient Share among Non-TNF Biologics in the Treatment of Rheumatoid Arthr

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that among recently treated rheumatoid arthritis patients, U.S. patient share of Bristol-Myers Squibb’s selective costimulation modulator Orencia was more than double the patient share of Biogen Idec/Roche’s B-cell inhibitor Rituxan in the fourth quarter of 2010. During the same time period, Roche’s interleukin-6 inhibitor Actemra received only minimal patient share, which is not surprising as the drug was only recently approved for rheumatoid arthritis by the U.S. Food and Drug Administration in January 2010.

According to Treatment Algorithms in Rheumatoid Arthritis, a higher percent of switches to Rituxan were from Orencia than vice versa during the most recent study period. The analysis also finds that of recently treated patients, a higher percentage of switches to Orencia were from a TNF-alpha inhibitor compared with the percent of switches to Rituxan from a TNF-alpha inhibitor.

“TNF-alpha inhibitors are the most commonly prescribed biologics for rheumatoid arthritis and non-TNF biologics are largely reserved for patients who fail TNF-alpha inhibitors or for patients in whom TNF-alpha inhibitors are contraindicated,” said Decision Resources Analyst Benjamin Guikema, Ph.D. “Our data indicate that Orencia is most likely to be used after a TNF-alpha inhibitor and tends to precede Rituxan in the treatment algorithm.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends and the factors that drive therapy choice, from diagnosis through multiple courses of treatment, for a specific disease.

Note to editors: Reporters needing specific patient-share numbers, please contact Lisa Osgood at [email protected].

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.